Clinical Trials Browser

Phase 2 × Breast Neoplasms × stenoparib × Clear all

NCT03562832 2025-01-23

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Phase 2 Completed

Breast Neoplasms